News
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic, Inc. to Participate in Investor Conference in December
Immunic, Inc. to Participate in Investor Conference in December. Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing therapies for chronic inflammatory and autoimmune diseases, announces participation in Piper Sandler 36th Annual Healthcare Conference in New York -
-
-
COMMUNIQUÉ DE PRESSE
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Immunic announces publication of phase 1/1b clinical trial data of IMU-856 in The Lancet Gastroenterology & Hepatology. Positive results in celiac disease patients. Potential new approach for gastrointestinal diseases -
-
-
COMMUNIQUÉ DE PRESSE
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2024 financial results, positive Phase 3 ENSURE Program interim analysis. Twin Phase 3 ENSURE trials and Phase 2 CALLIPER trial on track. Webcast held on Nov 7. IMUX stock update -
